UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
United Therapeutics Corp (UTHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, solid financial performance, and favorable analyst sentiment, making it a compelling investment opportunity despite the lack of immediate trading signals.
The stock's technical indicators show mixed signals. The MACD is negative and expanding downward, indicating potential short-term bearish momentum. However, the RSI is neutral at 63.864, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an overall upward trend. The pre-market price of $580.5 is above the pivot level of $570.19, indicating bullish sentiment. Key resistance levels are at $583.45 and $591.641.
Strong analyst sentiment with multiple price target upgrades, including RBC Capital and Raymond James setting a $700 price target.
Positive clinical trial results for Tyvaso in idiopathic pulmonary fibrosis, which positions the drug for label expansion and significant future revenue growth.
Solid financial performance in Q4 2025, with revenue up 7.38% YoY, net income up 20.91% YoY, and EPS up 23.99% YoY.
Gross margin decreased by 3.10% YoY in Q4 2025, which could indicate rising costs or pricing pressures.
Stock trend analysis shows a 60% chance of short-term declines (-1.39% in the next day, -4.8% in the next week, -2.78% in the next month), which may concern short-term traders.
United Therapeutics delivered strong financial results in Q4 2025. Revenue increased by 7.38% YoY to $790.2 million, net income rose by 20.91% YoY to $364.3 million, and EPS grew by 23.99% YoY to $7.7. However, gross margin dropped slightly to 86.91%, down 3.10% YoY.
Analysts are highly optimistic about United Therapeutics. Recent ratings include multiple upgrades and price target increases, with RBC Capital, Raymond James, and others setting targets as high as $700. Analysts highlight the strong potential of Tyvaso in idiopathic pulmonary fibrosis and its expected market dominance.
